SI-BONE Inc. Initiates Voluntary Recall; Extends Lease to Oct 2026

What Happened

• SI-BONE, Inc. (SIBN) filed an 8-K on September 11, 2026 disclosing two material items: (1) a voluntary recall of certain iFuse TORQ implants due to compromised tube packaging that may affect sterility, and (2) a Fourth Amendment to its office lease extending the lease term for its Santa Clara headquarters for one month (October 1–31, 2026).
• The company initiated the recall on August 21, 2026 after its tube-packaging subcontractor notified SI-BONE on August 17, 2026 of packaging failures. SI-BONE reported the correction and removal to the FDA on August 31, 2026 and recommended the action be classified as a Class II recall.

Key Details

• Recall: 98 iFuse TORQ implants from specific lots were distributed to the field; 2 of those had been implanted (no infections or adverse events reported to date).
• Scope: SI-BONE estimates ~3,900 implants will need repackaging and re-sterilization (includes recalled lots and other impacted inventory still under company control); most impacted inventory is quarantined.
• Financial impact: Company expects to record an aggregate gross charge of up to approximately $150,000 in Q3 and Q4 cost of goods sold related to recall, repackaging and re-sterilization; SI-BONE intends to seek recovery from the tube manufacturer but recovery is not guaranteed.
• Lease amendment: Fourth Amendment to Lease (dated Sept 11, 2026) extends term for one month (Oct 1–31, 2026) for the company’s 21,848 sq ft HQ at 471 El Camino Real, Santa Clara, CA; base rent for October is $43,696 and the company will continue paying its share of operating expenses and taxes through the expiration date.

Why It Matters

• Patient safety and regulatory risk: The recall addresses a sterility risk that could lead to infection and revision surgery; SI-BONE is working with the FDA and investigating the root cause, which is important for regulatory compliance and clinical confidence.
• Financial and operational impact: The immediate direct cost appears limited (up to ~$150k expected charge) and SI-BONE does not expect the recall to materially affect Q3 revenue or its ability to supply physicians, but costs and potential liability remain uncertain and recovery from the tube manufacturer is not assured.
• Corporate housekeeping: The one-month lease extension and modest rent amount are operational details that keep the headquarters lease in force while longer-term arrangements are settled.